nach oben

Erschienen in:

01.07.2010 | Original Article

Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia

verfasst von: Ellen Christina Obermann, Caroline Arber, Martine Jotterand, Andre Tichelli, Petra Hirschmann, Alexandar Tzankov

Erschienen in: Annals of Hematology | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Mutations of the Fms-like tyrosine kinase 3 (FLT3) can be detected in a significant number of acute myeloid leukemias (AML). Seventy-five cases of acute myeloid leukemia were evaluated for FLT3-internal tandem duplications (ITD) by polymerase chain reaction. Paraffin-embedded formalin-fixed trephine biopsies of these cases were evaluated for expression of phosphorylated signal transducer and activator of transcription 1 (pSTAT1), pSTAT3, and pSTAT5. Specific expression of pSTAT5 was proven in leukemic blasts in situ by double staining with a blast-specific marker. Expression of pSTAT5 in ≥1% of blasts was highly predictive of FLT3-ITD. Neither expression of pSTAT1 nor pSTAT3 were associated with FLT3 mutations. Altogether we conclude that pSTAT5 expression can precisely be assessed by immunohistochemistry in routinely processed bone marrow trephines, STAT5 is highly likely the preferred second messenger of FLT3-mediated signaling in AML, and expression of pSTAT5 is predictive of FLT3-ITD.

Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P et al (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459–463CrossRefPubMed

Choudhary C, Muller-Tidow C, Berdel WE, Serve H (2005) Signal transduction of oncogenic Flt3. Int J Hematol 82:93–99CrossRefPubMed

Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y et al (2006) FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 20:1414–1421CrossRefPubMed

Tzankov A, Sotlar K, Muhlematter D, Theocharides A, Went P, Jotterand M et al (2008) Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol 61:958–961CrossRefPubMed

Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074–3080PubMed

Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–1759CrossRefPubMed

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439CrossRefPubMed

Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y et al (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103:1901–1908CrossRefPubMed

Reilly JT (2003) FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 44:1–7CrossRefPubMed

10.

Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911–1918PubMed

11.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

12.

Krebs DL, Hilton DJ (2001) SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19:378–387CrossRefPubMed

13.

Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19:2474–2488CrossRefPubMed

14.

Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J et al (1996) STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87:1692–1697PubMed

15.

Xia Z, Baer MR, Block AW, Baumann H, Wetzler M (1998) Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 58:3173–3180PubMed

16.

Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P et al (2009) Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 22:476–487CrossRefPubMed

17.

Coffer PJ, Koenderman L, de Groot RP (2000) The role of STATs in myeloid differentiation and leukemia. Oncogene 19:2511–2522CrossRefPubMed

18.

Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A (1995) Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14:1166–1175PubMed

19.

Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R et al (2000) Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 192:719–728CrossRefPubMed

20.

Castagne C, Muhlematter D, van Melle G, Gachoud V, Jotterand Bellomo M (1997) Effect of conditioned media, nutritive elements, and mitotic synchronization on the accuracy of the cytogenetic analysis in acute nonlymphocytic leukemia patients presenting with inv(16)/t(16;16) or t(15;17). Cancer Genet Cytogenet 94:106–112CrossRefPubMed

21.

Mitelman F (1995) An international system for human cytogenetic nomenclature. Karger, Basel

22.

Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104:550–557CrossRefPubMed

23.

Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–266CrossRefPubMed

24.

Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S (2009) Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. doi:10.3109/10428190903370338

25.

Pallis M, Seedhouse C, Grundy M, Russell N (2003) Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications. Leuk Res 27:803–805CrossRefPubMed

26.

Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R et al (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein–Barr virus (EBV)-related lymphoma cell lines. Blood 88:809–816PubMed

27.

Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E (2001) Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15:1923–1931PubMed

28.

Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W (2002) Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 30:262–271CrossRefPubMed

29.

Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP et al (2006) Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108:1339–1345CrossRefPubMed

30.

Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C et al (2003) The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 101:1494–1504CrossRefPubMed

31.

Stirewalt DL, Meshinchi S, Radich JP (2003) Molecular targets in acute myelogenous leukemia. Blood 17:15–23CrossRef

32.

Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG et al (2009) Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113:4052–4062CrossRefPubMed

Titel: Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia
verfasst von: Ellen Christina Obermann
Caroline Arber
Martine Jotterand
Andre Tichelli
Petra Hirschmann
Alexandar Tzankov
Publikationsdatum: 01.07.2010
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 7/2010
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-009-0890-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2010

Acquired erythropoietic protoporphyria

Resolution of invasive fungal sinusitis in immunocompromised patients: neutrophil count is crucial beside a combined medical and surgical approach

Idiopathic neutropenia with fewer than 5% dysplasia may be a distinct entity of idiopathic cytopenia of undetermined significance

Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment

Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome